Evidence map›Paper›PMID 33752206›Full record

ReviewAmerican journal of nephrology2021

Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy.

John S Thurlow, Megha Joshi, Guofen Yan, Keith C Norris, Lawrence Y Agodoa, Christina M Yuan, Robert Nee

2 registry-linked trialsAbstract readReview
In one paragraph

Review in American journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 438 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
438citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05837988 unknown statusnot on this mapstarted 2023, after this paper: background citation

Construction of Symptom Network in Maintenance Hemodialysis Patients

TypeobservationalSponsorRenJi HospitalRan2023 to 2025Enrolled517ConditionsSymptom Cluster, Symptoms and Signs, Hemodialysis Complication, Hemodialysis-Associated Pruritus
NCT06355466 completednot on this mapstarted 2022, after this paper: background citation

Evaluation of Duration of the Long-term Hemodialysis Catheters Patency and Its Effecting Factors in Chronic Hemodialysis Patients in Golestan Province in 1400-1401

TypeobservationalSponsorGolestan University of Medical sciencesRan2022 to 2023Enrolled156ConditionsVascular Access Devices
3 · Its place in the literature

Who cites it

438 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Intradialytic Exercise: Effects on Arterial Stiffness and Gait Speed in Patients Undergoing Hemodialysis.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Trial
  18. Review
  19. Article
  20. Article

378 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John S ThurlowNephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Megha JoshiNephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Guofen YanDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Keith C NorrisDepartment of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
Lawrence Y AgodoaOffice of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Christina M YuanNephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Robert NeeNephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA, robert.nee.civ@mail.mil.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Center for Health Improvement of Minority ElderlyP30AG021684 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Homero Erwin del Pino · 2002 to 2026
$19.7M
Racial and ethnic disparities in kidney outcomes among people at risk for chronic kidney disease (CKD)R01DK112008 · NIDDK · UNIVERSITY OF VIRGINIA · PI Julia J Scialla, Guofen Yan · 2018 to 2026
$2.2M
Intramural NIH HHS Z99 DK999999NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NIA NIH HHS P30 AG021684NIDDK NIH HHS R01 DK112008
6 · The paper itself

Abstract

backgroundThe global epidemiology of end-stage kidney disease (ESKD) reflects each nation's unique genetic, environmental, lifestyle, and sociodemographic characteristics. The response to ESKD, particularly regarding kidney replacement therapy (KRT), depends on local disease burden, culture, and socioeconomics. Here, we explore geographic variation and global trends in ESKD incidence and prevalence and examine variations in KRT modality, practice patterns, and mortality. We conclude with a discussion on disparities in access to KRT and strategies to reduce ESKD global burden and to improve access to treatment in low- and middle-income countries (LMICs). SUMMARY: From 2003 to 2016, incidence rates of treated ESKD were relatively stable in many higher income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. Unadjusted 5-year survival of ESKD patients on KRT was 41% in the USA, 48% in Europe, and 60% in Japan. Dialysis is the predominant KRT in most countries, with hemodialysis being the most common modality. Variations in dialysis practice patterns account for some of the differences in survival outcomes globally. Worldwide, there is a greater prevalence of KRT at higher income levels, and the number of people who die prematurely because of lack of KRT access is estimated at up to 3 times higher than the number who receive treatment. Key Messages: Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in LMICs where health care resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and development of affordable and cost-effective KRT. Achieving global equity in KRT access will require concerted efforts in advocating effective public policy, health care delivery, workforce capacity, education, research, and support from the government, private sector, nongovernmental, and professional organizations.

Indexed as

Healthcare DisparitiesRenal Replacement TherapyAfricaArteriovenous Shunt, SurgicalChinaDeveloped CountriesDeveloping CountriesGlobal HealthHumansIncidenceIndiaKidney Failure, ChronicPrevalenceRenal DialysisSurvival RateUnited StatesDialysisDisparitiesEnd-stage kidney diseaseGlobal epidemiologyHemodialysisIncomeKidney replacement therapyKidney transplantMortalityPeritoneal dialysis

Identifiers

PMID33752206
PMCPMC8057343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.